[Correlations between PRL and 17-beta-E in human breast cancer].
The authors study the correlation existing between prolactin and E-17-beta in breast cancer. In both premenopausal and post-menopausal patients prolactin may be useful as an evolutive marker. Prolactin increases particularly as a consequence of the metastatic growth. E-17-beta shows no variation when studied during the luteal phase, diminishes after the extirpation of the primitive tumor, and augments again with metastases development. After chemotherapy the amount of E-17-beta becomes almost undetectable. No correlation was found between prolactin and E-17-beta; apparently, the prolactin increase does not depend directly from the amount of circulating estradiol, but relies on the activity of the hypothalamic-hypophyseal system. With regard to E-17-beta, this product also augments after ovariectomy, suggesting an ectopic production starting on adrenal gland precursors, perhaps modulated by prolactin.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D004958:Estradiol / Q000097:blood*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008183:Luteal Phase; D008593:Menopause; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010052:Ovariectomy; D011184:Postoperative Period; D011379:Prognosis; D011388:Prolactin / Q000097:blood*
D004958:Estradiol; D003520:Cyclophosphamide; D011388:Prolactin; D005472:Fluorouracil; D008727:Methotrexate
Correlaciones entre PRL y E. 17 beta en el cáncer de mama humano.